RVMD vs. BNTX, TEVA, SMMT, GMAB, VTRS, RDY, ASND, QGEN, MRNA, and BBIO
Should you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Moderna (MRNA), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.
Revolution Medicines vs. Its Competitors
Revolution Medicines (NASDAQ:RVMD) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.
Revolution Medicines has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.
Revolution Medicines currently has a consensus price target of $69.92, indicating a potential upside of 76.89%. BioNTech has a consensus price target of $135.80, indicating a potential upside of 34.97%. Given Revolution Medicines' stronger consensus rating and higher possible upside, research analysts clearly believe Revolution Medicines is more favorable than BioNTech.
Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -12.20%. BioNTech's return on equity of -1.84% beat Revolution Medicines' return on equity.
In the previous week, Revolution Medicines had 2 more articles in the media than BioNTech. MarketBeat recorded 14 mentions for Revolution Medicines and 12 mentions for BioNTech. Revolution Medicines' average media sentiment score of 1.65 beat BioNTech's score of 1.28 indicating that Revolution Medicines is being referred to more favorably in the media.
94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Revolution Medicines has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Summary
Revolution Medicines beats BioNTech on 9 of the 15 factors compared between the two stocks.
Get Revolution Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revolution Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:RVMD) was last updated on 9/3/2025 by MarketBeat.com Staff
Free RVMD Stock Alerts